Brought to you by 
Veracyte buys Allegro Diagnostics for $20.3mm in cash and stock
30 Sep 2020
Executive Summary
Molecular cytology firm Veracyte Inc. acquired privately held Allegro Diagnostics Inc. (molecular diagnostics) for $20.3mm ($7.8mm in cash and 993k Veracyte shares, valued at $12.5mm based on the market average).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Veracyte buys Allegro Diagnostics for $20.3mm in cash and stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice